These findings validate the hypothesis that the EGFR C797S mutation causes metabolic changes, highlighting the potential therapeutic utility of targeting PDK1 to overcome osimertinib resistance in EGFR-mutant lung cancer cells. Here, EGFR is linked to lung carcinoma.